Actually, all approved drugs for HIV and a majority of the approved drugs for cancer are small molecules.
The rest of the Forbes column is dumb also. The proposed 12-year exclusivity period for branded biologics will not kill the economic incentive for companies to bring FoB’s to market, as the Forbes columnist alleges (see #msg-39869232).